Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them.
Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them. However, many approaches still struggle to reach target cells or tissues – either they fail to arrive, or their efficacy is low. In vivo therapies face numerous challenges, but despite these hurdles, 2025 has marked a year of remarkable progress.
CSPC Pharmaceutical Group Ltd. has obtained approval from the National Medical Products Administration (NMPA) in China to conduct clinical trials of SYH-2072 (tablets), a highly selective and potent aldosterone synthase inhibitor. It is being investigated as a potential treatment for uncontrolled hypertension and primary aldosteronism.
Fortvita Biologics Inc. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, inflammatory disorders, diabetes, lung diseases, neurological disorders, obesity and renal disorders, among others.
Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them. However, many approaches still struggle to reach target cells or tissues – either they fail to arrive, or their efficacy is low. In vivo therapies face numerous challenges, but despite these hurdles, 2025 has marked a year of remarkable progress.
In a threshold event in the U.S., Medicare is planning to break through its obesity coverage barrier with a voluntary test of a model designed to enable Medicare Part D plans and state Medicaid programs to cover GLP-1 drugs prescribed for weight management.
Needle-phobic obesity patients got their first workaround with the U.S. FDA clearance of Novo Nordisk A/S’ once-daily GLP-1 Wegovy (semaglutide) pill, the first of its kind.
Aché Laboratórios Farmacêuticos SA has identified compounds acting as sodium/glucose cotransporter 1 (SGLT-1), SGLT-2 and dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cardiovascular, renal and metabolic diseases.
Enveda has obtained IND clearance from the FDA and commenced dosing in a phase I study of ENV-308, a once-daily oral therapy designed for chronic weight management.
RSS
